Alvotech provides update on status of biologics license applications for avt02 and avt04

Reykjavik, iceland, jan. 19, 2024 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of alvotech's facility in iceland by the u.s. food and drug administration (fda) which started on january 10, 2024, has been concluded. following the fda inspection, alvotech received a form 483 with one observation. alvotech expects to provide the fda with a response in the following days.
ALVO Ratings Summary
ALVO Quant Ranking